‘‘(3) FORMAT.—The educational materials provided under paragraph (1) may be— 

‘‘(A) in formats such as webinars, continuing education modules, videos, fact sheets, infographics, stakeholder tool- kits, or other formats as appropriate and applicable; and 

‘‘(B) tailored for the unique needs of health care pro- viders, patients, caregivers, and other audiences, as the Secretary determines appropriate. 

‘‘(4) OTHER INFORMATION.—In addition to the information described in paragraph (2), the Secretary shall continue to publish— 

‘‘(A) the action package of each biological product licensed under subsection (a) or (k) of section 351; or 

‘‘(B) the summary review of each biological product licensed under subsection (a) or (k) of section 351. 

‘‘(5) CONFIDENTIAL AND TRADE SECRET INFORMATION.—This subsection does not authorize the disclosure of any trade secret, confidential commercial or financial information, or other matter described in section 552(b) of title 5. 

‘‘(b) CONTINUING EDUCATION.—The Secretary shall advance education and awareness among health care providers regarding biological products, including biosimilar biological products and interchangeable biosimilar biological products, as appropriate, including by developing or improving continuing education pro- grams that advance the education of such providers on the pre- scribing of, and relevant clinical considerations with respect to, biological products, including biosimilar biological products and interchangeable biosimilar biological products.’’. 

Approved April 23, 2021. 

